442 results on '"Garibotto V"'
Search Results
2. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
3. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
4. A kinetics-based approach to amyloid PET semi-quantification
5. Guide à la lecture et interprétation de l’imagerie PET des plaques amyloïdes
6. Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging
7. Neurologic imaging
8. Brain Tumors
9. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease
10. International consensus on the use of tau PET imaging agent F-18-flortaucipir in Alzheimer's disease
11. Changes in brain glucose metabolism in subthalamic nucleus deep brain stimulation for advanced parkinson's disease
12. Molecular neuroimaging with PET/MRI
13. Education and occupation provide reserve in both ApoE ε4 carrier and noncarrier patients with probable Alzheimer’s disease
14. Optimized objective SPM analysis improves accuracy of [18F]FDG-PET imaging in dementia diagnosis: EP3245
15. Severe early basal ganglia hypometabolism in neurodegeneration with brain iron accumulation
16. Pre–clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis
17. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD
18. Microglial activation in Parkinsonʼs disease and Lewy body dementia: A PET study: Poster Presentation No.: P056
19. MAP vs RLS methods for [11C]MP4A PET pixel-wise quantification in neurodegenerative diseases discrimination: Poster Presentation No.: P006
20. Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism
21. Striatal dopamine deficiency is associated with increased striatal glucose metabolism in Dementia with Lewy Bodies
22. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
23. Quality Assurance of Small Animal Irradiation: Validation of a 3D-Printed Phantom for “Quasi In-Vivo” Dosimetry
24. The need for standardization and larger clinical studies in emerging indications to [18F]FDG PET brain PET: autoimmune encephalitis
25. Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome?
26. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: A 18F-MISO PET/MRI Imaging Study
27. Hybrid PET/MRI in neuro-imaging
28. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting
29. Clinical applications of hybrid PET-MR
30. Corrigendum to Invivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease
31. Editorial: is ischemic stroke an inflammatory disease?
32. Imaging in Neurological and Vascular Brain Diseases (PET/CT)
33. The role of neuroimaging in the early diagnosis of Alzheimer's disease
34. In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder
35. SPM analysis of PET neurological studies by current generation PT/CT systems
36. Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging.
37. In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia
38. Early but different PET cholinergic impairment in AD and DLB and correlations with long term memory scores
39. Subcortical and deep cortical atrophy in frontotemporal lobar degeneration
40. Teaching NeuroImages: Drug-induced parkinsonism with asymmetrical putaminal DaT binding
41. Significance of 18F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients
42. MAP method for [11C]MP4A PET pixel wise quantification: a comparative study in aMCI, pAD and LBD
43. MAP vs RLS methods for [11C]MP4A PET pixel-wise quantification in neurodegenerative diseases discrimination
44. Microglial activation in Parkinson's disease and Lewy body dementia: A PET study
45. A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset
46. Central GABAergic dysfunction in primary dystonia
47. MAP vs RLS methods for [C-11]MP4A PET pixel-wise quantification in neuro degenerative diseases discrimination
48. Microglial activation in Parkinson's disease and Lewy Body Dementia: PET studies and proteomic analysis
49. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence
50. [11C]MP4A Bayesian quantification of AChe activity at pixel and ROI level in normal and Alzheimer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.